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Cancer is a complex disease in which unrestrained cell proliferation results in tumour development. 
Extensive research into the molecular mechanisms underlying tumorigenesis has led to the 
characterization of oncogenes and tumour suppressors that are key elements in cancer growth and 
progression, as well as that of other important elements like microRNAs. These genes and miRNAs 
appear to be constitutively deregulated in cancer. To identify signatures of miRNA-mRNA interactions 
potentially conserved in essential cancer pathways, we have conducted an integrative analysis of 
transcriptomic data, also taking into account methylation and copy number alterations. We analysed 
18,605 raw transcriptome samples from The Cancer Genome Atlas covering 15 of the most common 
types of human tumours. From this global transcriptome study, we recovered known cancer-associated 
miRNA-targets and importantly, we identified new potential targets from miRNA families, also 
analysing the phenotypic outcomes of these genes/mRNAs in terms of survival. Further analyses could 
lead to novel approaches in cancer therapy.
Unrestrained cell proliferation is the principal hallmark of cancer, provoked by DNA insults and other events. 
These insults produce mutations in genes that might alter their expression and/or function, deregulating many 
physiological pathways and provoke chromosomal damage, events that drive oncogenic transformation and 
tumour progression1. A physiological response is triggered by cells to restrain genomic instability by removing or 
repairing DNA lesions, widely known as the DNA damage response pathway (DDR)2. Different levels of damage 
produce different responses, such that mild DNA damage induces a reparative response, while severe damage 
activates cell death in a regulated manner. Distinct proteins are involved in these processes. For instance, p53 
contributes to the differential expression of pro-survival and pro-apoptosis genes, while ATM/ATR3 promotes 
cell death when there are many double strand breaks (DSB), activating CASP2, E2F1, P73 or CHEK1. In addition, 
several pathways are also relevant to restrain oncogenesis, by activating or repressing genes that control cell pro-
liferation and programmed cell death. In particular, the pathways controlling apoptosis, necrosis and senescence 
are of special interest, as are those involved in the DDR, the cell cycle, DNA replication and telomere elongation, 
all of which constitute an intricate network in which there is extensive cross-talk that influences events like cancer 
initiation and progression4. Indeed, the intense research carried out into these pathways has helped characterize 
a large number of mechanisms directly implicated in tumour development5.
To further our understanding of cancer and to develop new treatments, several international initiatives have 
set out to generate complete libraries of tumour types. For example, The Cancer Genome Atlas (TCGA) consor-
tium provides information extracted from a wide variety of cancers using different techniques, housing datasets 
containing DNA methylation samples, whole genome and whole exome sequences, transcriptome data (RNASeq 
and small RNASeq), etc. Previous studies identified genes related to cancer malignancy by comparing tumour tis-
sue with normal tissue samples6. Such studies yielded relevant genes, of which oncogenes and tumour suppressor 
genes received most attention as they have the potential to convert a normal cell into a cancer cell. Oncogenes are 
often mutated or expressed at high levels in tumour cells, while tumour suppressor genes may also be mutated or 
expressed more weakly than normal. TP537 or FOS8 are examples of tumour suppressor genes where mutations, 
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deletions and/or repression are implicated in processes related to cancer development. Similarly, the oncogenes 
E2F33 and AURKA9 induce cell growth and proliferation when mutated or over-expressed, driving cells through 
the cell cycle checkpoints.
In the past decade, the role of microRNAs (miRNAs) in cancer and in cell proliferation has gained signifi-
cance given their critical role in regulating target genes. These are single stranded non-coding RNAs of 19–22 
nucleotides commonly involved in mRNA destabilization and degradation10,11. miRNAs from the same family 
share a high degree of sequence homology and they are commonly found in clusters, the components of which 
are expressed simultaneously, in turn resulting in a tendency to regulate genes with similar functions12. Thus, the 
inappropriate expression of miRNAs that regulate key genes like oncogenes or tumour repressor genes can lead 
to tumour development, and families such as miR-15, miR-1 and let-7 have frequently been related with cancer 
growth and metastasis.
The specific miRNAs that are capable of transforming normal cells into tumour cells are known as oncomiRs. 
For instance, the miR-17/92 cluster, a polycistron RNA that encodes for 6 different miRNAs, was the first oncomiR 
described. Its over-expression is related to E2F113 and AIB114 down regulation, which in turn produces tumours 
by inducing cell growth and proliferation. Conversely, there is another subset of miRNAs, the tumour suppressor 
miRNAs or anti-oncomiRs, among which we can distinguish the miR-143/145 cluster that is transcribed as a 
bicistronic unit. Relative to normal cells, these miRNAs are expressed more weakly in colon cancer cells and in 
breast, lung, head and neck, and bladder cancers15. The miR-143/145 cluster targets a large number of genes and 
their deregulation is thought to be one of the earliest events in cancer development16.
The relationships between miRNAs and their mRNA targets are difficult to study experimentally. Current 
methods are complex, expensive and must overcome technical challenges like tissue specificity, weak expression, 
3′ UTR selection and miRNA stabilization17. Some techniques measure mRNA expression upon the modification 
of miRNA expression using luciferase assays or other proteomic assays like pulsed stable isotope labelling with 
amino acids in cell culture (pSILAC). These approaches serve to quantify the protein derived from the mRNA 
regulated by different levels of miRNA18. Given the known level of complexity, computational predictions of puta-
tive miRNA-mRNA targets emerge as a complementary approach to facilitate the experimental characterization 
of relevant miRNAs. The most frequent procedures are based on seed sequence complementarity, evolutionary 
conservation and thermodynamic stability19. Moreover, additional steps can be implemented to reduce the una-
voidable number of false positives obtained from software prediction. In this regard, miRNA target prediction can 
be improved by using inverse correlated profiles from over-expressed miRNAs and down-regulated genes from 
the same tumour samples, and vice versa20.
One relatively unexplored issue is the potential identification of specific miRNA-mRNA interactions within 
well-established cancer pathways that are amenable for therapeutic targeting. To investigate whether such inter-
actions are associated with cancer, an integrated analysis of several different tumour types within a comprehensive 
statistical framework could aid the discovery of specific cancer related miRNA-mRNA signatures. In addition, the 
analyses of these signatures in different tumours, accounting for additional factors like gene methylation (MET) 
and copy number alterations (CNAs), could provide relevant information regarding the signature’s stability. In the 
context of survival, such information is likely to be useful to define novel therapeutic strategies21.
Results
Genome-wide analysis of individual tumours. Thousands of samples were examined for each of the 15 
tumour types analysed here (see Supplementary Table 1 for details), performing differential expression analyses 
to identify deregulated genes and miRNAs. Only those exhibiting reliable FDR values (FDR < 0.05) and signifi-
cantly altered expression (absolute log2FC > 1) were selected for further analysis. Details regarding the analysis of 
RNASeq and small RNASeq samples from each individual tumour type are described in the Supplementary Text.
Integrative data analysis for the set of 15 tumours. We performed a comprehensive statistical anal-
ysis on a set of 15 tumours to identify novel miRNA-mRNA associations that might commonly be deregulated. 
To this end, we extracted data on differentially expressed genes and miRNAs, comparing samples from healthy 
subjects and tumour patients from each tumour (see Fig. 1 for the number of significantly deregulated genes and 
miRNAs).
Pathway enrichment. In order to estimate the deregulation of a pathway as a whole, we adopted the net effect 
of all the genes in a pathway rather than the individual contribution of only a few genes. To this end, dereg-
ulated genes from each tumour type were extracted and pathway enrichment was studied. Consequently, we 
inferred that pathways differed mildly across the distinct tumour types (Fig. 2). However, when the pathways 
were compared in all the cancer types, we observed that significantly altered pathways known to be related to 
cancer inhibition (apoptosis, necrosis and senescence, or DDR) frequently appeared to be depleted in differen-
tially expressed genes. Adopting this approach means that genes may exhibit the opposite tendency in terms of 
expression to that of the pathway as a whole. For instance, although TP53 is up-regulated in CHOL, de-regulation 
of the remaining genes in the pathway produce a net silencing of the pathway in this particular cancer. On the 
other hand, TP53 is down-regulated in several tumour types (BRCA, ESCA, KIRP, LUAD, LUSC, and PRAD) 
in agreement with our observations. Indeed, while certain genes may frequently be mutated in cancer, in some 
cases these mutated forms are not functional. One such example is the aforementioned TP53, which is often 
over-expressed in cancer when it carries mutations, although many of these overexpressed mutated variants have 
lost their original function22. As such, non-functional overexpressed forms of TP53 are not capable of triggering 
apoptosis. We observed a similar trend for other genes and while we found MDM2 to be up-regulated in most 
tumours (Supplementary Table 6), the overall senescence pathway was dampened (Fig. 2). The same applies to 
RB1, which is up-regulated in 2 tumour types (CHOL and HNSC) but it is down-regulated in another 4 tumours 
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(BLCA, LIHC, LUAD, LUSC), consistent with the effect on the whole pathway. Other pathways exhibited distinct 
trends depending exclusively on the tumour type, such as DNA replication, telomere elongation and cell cycle 
(more details are available in Supplementary Table 2).
Genes differentially expressed across all tumour types. Significantly deregulated genes were retrieved from all 
types of tumours (for details see Supplementary Text), yet in keeping with other procedures23,24, only those genes 
differentially expressed in at least 8 different tumour types were considered for further analysis. This cut-off was 
established as it reflected the best combination of tumour types, and the best enrichment of cancer-related genes 
and miRNA-related genes. To this end we compiled known cancer genes from COSMIC25 and the network of can-
cer genes (NCG 5.0 26 ), which offers a comprehensive list of known cancer genes (more than 600). Using different 
thresholds for the number of tumour types (from 5 to 10), the figure of 8 tumours appeared to be the cut-off with 
the highest odds ratio (enrichment in known cancer genes) with a significant right-tailed Fisher false discovery 
rate (FDR) of 1.54E-02 for COSMIC and 1.87E-03 for NCG (for more details, see Supplementary Tables 3 and 4).
From the total of 147 significantly deregulated genes (see Supplementary Table 6), we identified SCP24 as the 
only gene over-expressed in all tumour types. We also found SYNE1 (relevant to the cell cycle) to be the most 
strongly downregulated gene in the 15 tumours studied (see Fig. 3 for the distribution of both SPC24 and SYNE1). 
From the remaining differentially expressed genes, 11 belonged to the apoptosis pathway, in which E2F1 and 
CLSPN were deregulated in 14 and 12 tumour types, respectively. In other pathways, 126 genes appeared to be 
misregulated in cell cycle pathways and 21 were altered in the DDR, where the oncogenes CDT1, PLK1 and DTL 
were among the most prominent deregulated genes. In the DNA replication pathway, 26 genes were de-regulated 
including the previously identified E2F1, CDT1 and the oncogene GINS2 as the most significantly affected genes. 
Of the 29 genes for senescence that were deregulated, Ubhc10/UBE2C was the most strongly deregulated. Finally, 
the polymerases DNA2 and POLE2 appeared to be deregulated in the telomere pathway in a large number of 
tumours.
miRNAs differentially expressed in tumours. We identified 95 miRNAs that were significantly deregulated in at 
least 8 of the 15 different tumour types studied (see Supplementary Table 7). As indicated above, this cut-off was 
selected by performing enrichment at different thresholds using data from the cancer related miRNAs stored in 
Figure 1. Number of differentially expressed genes and miRNAs (over-expressed and repressed) in each 
tumour type. 
Figure 2. Pathway enrichment analysis of the differentially expressed genes in each tumour type. Statistical 
significance threshold was set at P < 0.05. Enrichment is indicated by log2 of the odd ratio. In blue, positively 
enriched pathways; in red, negatively enriched pathways (more altered than expected and less altered, 
respectively).
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OncomirDB27, a database that is a high-confidence reference resource for studying miRNAs related to cancer. 
Among the up-regulated miRNAs that appear in the vast majority of tumours analysed, we found an oncogenic 
cluster that was over-expressed in 14 tumours, formed by miR-182, miR-96 and miR183, and miR-4746 that was 
over-expressed in all the tumours analysed (Fig. 3). Conversely, the anti-oncomiRs miR-145, miR-139 and miR-
195 were the most strongly down-regulated miRNAs in our dataset. Interestingly, miR145 and miR143, which 
were also strongly downregulated (see Fig. 3), belong to the tumour-suppressor miRNA cluster miR143/145 
implicated in the initial steps of tumorigenesis15. Moreover, miR-195 and miR-139 are also well-known tumour 
suppressor miRNAs28.
Conserved deregulated miRNA-mRNA target interactions. The 147 genes and 95 miRNAs differentially expressed 
in the majority of tumour types were used to study potential miRNA-mRNA interactions. As miRNAs commonly 
repress gene expression through the RNA interference pathway, significant negative correlations in expression 
were expected to reflect the reliability of possible interactions. Accordingly, only inverse differential expression 
of miRNA-mRNA pairs predicted from miRGate29 were evaluated with a genomic agreement ≥ 2 (for details see 
methods).
We analysed the correlation between gene expression and miRNA expression of the predicted pairs using 
linear regression models that included the log-transformed gene expression values as the response, and the copy 
number alterations (CNAs), gene methylation (MET) and log-transformed miRNA expression values as explan-
atory variables (Supplementary Table 11). For each of the 41 significant gene-miRNA pairs, individual models 
were constructed for every cancer type, and a joint analysis was also performed that included all the samples 
from all the different types of cancer. In the latter, “cancer type” was also included as an explanatory variable (see 
methods). Thirty-six out of the 41 pairs (Fig. 4) exhibited a statistically significant negative correlation in the joint 
analysis (Supplementary Figure 1).
From these 36 pairs, we found 25 novel interactions not described in other specialized databases like 
OncomirDB27, miRCancer30 and miRTarBase31. Most of these interactions involved cell cycle related genes, like 
SPC24 and CDC20 (regulated by the anti-oncomiR miR-139), and PKMYT1 (regulated by the tumour suppres-
sor miR-195). The senescence pathway was also represented and while most of the associations identified were 
known, novel ones were found like HMGA2/miR-139 and EZH2/miR-195. In the DNA replication pathway, the 
interaction of the MCM2 gene with the anti-oncomiR miR-139 was notable in the majority of tumours. Finally, 
the PRKAR2B/miR-135b pair was identified that includes the apoptosis related PRKAR2B gene.
To infer the pairs in which genes are targeted by few miRNAs (henceforth “high specificity” pairs), we iden-
tified 17 pairs with least secondary interactions that were positively enriched in the maximum possible number 
of tumours (see Methods). Interestingly, from these 17 significant pairs (adjusted p-value ≤ 0.05) several down-
regulated tumour-suppressor miRNAs (e.g., miR-let-7c, miR-139, miR-145 or miR-195) appeared to regulate 
Figure 3. Genes and miRNAs deregulated almost all of the studied tumour types: SPC24 is differentially 
overexpressed in all tumour types; SYNE1 is repressed in all tumour types; miR-4746-5p up-regulated in 
all the tumour types; and miR-145-5p, down-regulated in all tumour types except Cholangiocarcinoma 
(CHOL). 
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oncogenic genes related to the cell cycle and DDR pathways (BUB1B, AURKA, BIRC5, CENPK, BRCA1 and 
CHEK1). Eleven of these 17 resulting pairs had not been proposed previously (Fig. 5 and Supplementary 9). 
Indeed, these pairs are particularly interesting since the low promiscuity of the miRNA’s interactions favours their 
potential application as anti-miRNA oligonucleotides (AMOs) targets.
We also observed mRNA-miRNA pairs that only appeared in the two different lung tumour types (LUAD and 
LUSC). Linear regression models were established for these pairs to account for the CNAs and the MET status of 
the genes, as indicated above (Supplementary Figure 2, and Supplementary Table 12). We found 40 miRNA-mRNA 
pairs that involved 35 differentially expressed genes (4 being repressed, see Supplementary Figure 3) and 13 sta-
tistically deregulated miRNAs. The genes differentially expressed in these “exclusive lung” pairs were also dif-
ferentially expressed in other tumours. Moreover, in terms of the 13 miRNAs involved in these lung exclusive 
interactions, 16 of the 40 associations involve miR-miR-1976, which regulates 16 genes involved in cell cycle, 
apoptosis and the DDR. The second most strongly represented miRNA in these exclusive lung pairs was miR-let-
7b-5p, acting as a regulator in 10 interactions where 8 of the genes implicated also belong to cell cycle pathways, 
and another 2 to senescence pathways (Supplementary Figure 3). Notably, these two down-regulated miRNAs, 
which are in the most frequently obtained pairs, are apparently exclusive to these two tumour types as they don’t 
appear to be significantly repressed in any other tumour.
Survival Analysis. The 36 pairs that exhibited a statistically significant negative correlation in the multivar-
iate linear regression joint analysis (Supplementary Figure 1) were selected for a subsequent survival analyses 
(Fig. 6). The effect of gene expression on patient survival was explored separately for each cancer type using Cox 
proportional hazard models that included tumour stage. In these models, both tumour stage (encoded as one 
of two categories, i.e. Stage I-II vs Stage III-IV) and the log-transformed gene expression values were used as 
explanatory variables. Information on tumour stage was not available for prostate cancer (PRAD), so in this case 
tumour grade was employed as the explanatory variable (Gleason score 6–7 vs 8–10). Pairs that exhibited both a 
significant correlation between miRNA and gene expression, and a significant tumour stage-independent asso-
ciation between gene expression and patient survival, support the hypothesis that miRNA expression regulates 
gene expression and that the latter affects patient survival. We found miRNA-Gene Survival associations in 11 of 
the 36 selected pairs.
In 4 pairs, we found significant associations for at least two distinct tumour types. Then, the HJURP− 
miR-let.7c.5p in KIRP and LUAD, the CDC20/miR.139.3p in KICH and LUAD, the KIF20A/miR145.5.p pair in 
HNSC and LUAD, and the CASC5/miR.139.5p in BRCA and LUAD. The other 7 pairs were found in only one 
type of cancer each (Fig. 6 and Supplementary Table 13).
We repeated a similar analysis on the lung-exclusive predicted pairs identified in lung adenocarcino-
mas (LUAD) and squamous cell lung tumours (LUSC). Of the 74 gene-miRNA pairs originally predicted, 40 
exhibited a significant negative correlation in the multivariate linear regression joint analysis that included 
Figure 4. Relevant miRNA-mRNA targets found in the majority of the tumours studied. Lines represent 
interactions among miRNAs (green) and genes (blue). Continuous line indicates novel interactions, while 
dashed lines indicate validated interactions.
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tumour type, CNAs, MET and log-transformed miRNA expression as explanatory variables of gene expression 
(Supplementary Table 12 and Supplementary Figure 3). Of the 40 lung-exclusive pairs that passed the correlation 
analysis, we found 14 in which gene expression was also associated with patient survival after accounting for 
tumour stage (Supplementary Figure 4 and Supplementary Table 14). Notably, 13 were found in LUAD and only 
one in LUSC.
Discussion
The identification of miRNA-mRNA interaction pairs is gaining significant attention given their potential impli-
cations in devising novel therapies32. As such studies pose important experimental challenges, careful compu-
tational studies addressing this issue may help to identify novel therapeutic targets, as successfully described 
elsewhere for individual cancers33. A widely used method to evaluate the recurrence of miRNA-target associ-
ations is a rank-based method (REC, recurrent score34. Like PanMira35, this approach uses processed RNASeq 
and/or microarray data from tumour samples, excluding samples from healthy subjects. By contrast, alternative 
analyses using TCGA36,37 also include healthy samples as this provides a more accurate framework to understand 
target/miRNA relationships in cancer. As such, we have included samples from healthy subjects as controls to 
identify miRNA/mRNA associations from differentially expressed genes and miRNAs, avoiding other spurious 
interactions in principle not related to cancer.
Although much work has been done in individual tumours, a systematic analysis to infer conserved 
miRNA-mRNA interactions in different cancer types based on differential expression has yet to be performed on 
a large number of raw clinical samples. Thus, to determine if different tumours exhibit distinct miRNA-mRNA 
interactions, we have studied 15 of the most common tumour types in-depth. We analysed 18,605 RNASeq and 
miRNASeq raw data samples, following recommended procedures38 and applying restrictive filters to reduce false 
positives.
Our rationale was that miRNAs can act as onco-modulators of relevant target genes influencing their expres-
sion in tumours. Thus, by restricting the analyses to relevant cancer pathways, we could identify more suitable 
candidates. In the pathway analyses we found a general trend towards deregulation, although some genes within 
the pathways occasionally exhibited the opposite trend, even though the net effect of the remaining genes was to 
drive an overall “dampening” phenotype.
When considering individual tumour types, our results are consistent with previous findings where individual 
genes behaved as expected. SYNE1 is the most significantly repressed gene and its dysregulation has been related 
to glioblastoma39 and ovarian cancer40, among others. From the miRNA perspective, we identified important 
species previously related to tumour progression. For instance, we found miR-4746 to be over-expressed in all 
the tumours analysed, in accordance with previous studies41. Conversely, tumour suppressor miRNAs (miR-145, 
miR-139 and miR-195) are the most strongly down-regulated miRNAs in our dataset.
To identify suitable relations, as a first filter we only considered de-regulated genes and de-regulated miRNAs 
that exhibited inverted expression profiles. We next optimized the identification of miRNA binding to precise 3′ 
Figure 5. “Highly specific” pairs of interactions. Lines represent interactions among miRNAs (green) and 
genes (blue). Continuous line indicates novel interactions, while dashed lines indicate validated interactions.
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UTR sequences that should in principle trigger gene silencing. This effect is well accepted, given that most of the 
interactions involving miRNAs included the seed regions at 3′ UTRs42. To support this observation, additional 
studies in mammals revealed that there is a tendency to diminish target mRNA levels11. However, it is important 
to note that alternative mechanisms may be at play, including activation due to binding at the promoter or other 
regions of the gene43. Although non-canonical binding sites42,44 have been described for miRNAs, these are lim-
ited and they are not included in most of the available prediction software used here to identify target genes. Gene 
expression is also influenced by other important “pleiotropic” factors. Moreover, indirect interactions involving 
complex transcriptional networks of other genes and RNA species may also influence the expression of a given 
gene. While these influences deserve deeper exploration, their complexity and the lack of reliable data to model 
these elements in cancer makes this an issue beyond the scope of this work. Thus, for the purposes of simplicity 
we focus on the most parsimonious explanation, which is gene silencing by binding to 3′ UTR regions.
It is well known that methylation and copy number alterations affect gene expression, especially in can-
cer. From the original 41 pairs exhibiting significant inverted expression profiles, we filtered out some pairs by 
accounting for these factors with 36 consistent interactions remaining as both partners appeared to be deregu-
lated together. Of these 36 pairs, 25 had not previously been inferred, although individually most of the genes and 
miRNAs involved are known to be related to cancer development. An illustrative example is the SCP24/miR-139 
couplet, where involvement of the individual components is well-established (SPC24 and miR-139-5p45,46, while 
no experimental evidence is available for the pair. A subset of these 36 pairs (17 pairs), appear to be “highly spe-
cific” as both partners were not found with many other alternative interactors in the distinct tumour types. These 
specific associations are noteworthy, as they may be useful for the development of therapies due to the limited 
Figure 6. Survival with multifactorial Cox models in 15 tumours. Combined correlation and survival 
analysis for the selected 36 general miRNA-gene pairs. Every box summarizes the results of the correlation and 
survival analysis of a miRNA-gene pair (rows) in a particular cancer type (columns). Circles represent miRNA-
gene expression correlations, after accounting for CNAs and gene methylation. Negative correlations in red, 
and positive correlations in blue. Diamonds represent the log2 of the hazard ratio (HR) of Cox proportional 
hazards models that included tumor stage (or tumor grade, in the case of PRAD) and the log-transformed gene 
expression values as explanatory variables. Positive log2(HR), i.e. shorter survival, in shades of red. Negative 
log2(HR), i.e. longer survival, in shades of blue. All P-values were corrected for multi-hypothesis testing by the 
FDR method. Pairs reaching statistical significance (Adj. P < 0.05) in both miRNA-gen expression correlation 
and gene expression-survival association are indicated with thicker boxes.
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off-target effects. From these pairs, 11 interactions had not previously been described, while among associations 
that had already been experimentally confirmed were those of AURKA47 and BUB1B48 with miR-let-7c.
When comparing miRNA-mRNA interactions among tumour types, we observed that tumours of the same 
origin exhibited interactions not identified in the remaining tumours (Supplementary Figure 3), in particular 
lung cancers (LUAD and LUSC), and that these were mostly mediated by two types of miRNAs, miR-1976 and 
let-7b-5p. These miRNAs act as master regulators of genes belonging to the cell cycle and apoptosis pathways. 
Moreover, they are involved in the majority of these lung exclusive interactions, suggesting a potential value of 
these miRNAs as biomarkers for lung cancer. In fact miR-1976 is a potential tumour suppressor in lung cancer, as 
described in relation with the oncogene PLCE149.
There are many factors known to affect cancer prognosis. Cancer survival is ultimately the result of a very 
complex network of mechanisms that include tumour aggressiveness, operability, routine primary treatment, 
available secondary therapies, possible drug-resistance, patient age, their physical status, comorbidity, etc. All 
these factors differ radically among cancer types and affect their prognosis profoundly. For many years, clinicians 
have employed a number of clinical-pathological characteristics that have proven to be very useful to estimate 
cancer patient survival. Most notably, tumour stage and degree of differentiation have been used as prognostic 
factors in the diagnosis and management of most cancer types. For instance, patients with Stage III or IV can-
cers, where the malignant cells have already metastasized to lymph nodes or distant organs, exhibit much worse 
prognosis than patients with Stage I-II tumours. Similarly, patients with poorly differentiated tumours exhibit 
worse prognosis than patients with moderately or well-differentiated tumours. Patient age and gender are also 
typically employed as predictive markers of survival. In recent years, molecular markers of patient survival or 
of response to treatment have been steadily incorporated into clinical practice (ASCO, https://www.asco.org/
practice-guidelines and ESMO, http://www.esmo.org/Guidelines/Guidelines-News). Therefore, a single factor 
(gene, miRNA) should not be expected to produce a large effect on survival by itself, independently of the many 
confounding factors that potentially affect patient survival, especially across many different tumour types. As 
such, caution should be exercised regarding the associations between gene regulation by miRNAs and patient 
prognosis. Nonetheless, we have recovered known associations in our survival analyses, some of which have been 
studied extensively in many tumours, like the roles on prognosis of genes AURKA50–53 or BRCA154,55. We also 
found novel stage-independent prognostic genes not described in the literature like CASC5. This gene was previ-
ously described in lung cancer56, but not in breast cancer, which is the association found in this study. It is worthy 
to mention that its regulating miRNA (miR-139-5p) has been itself associated to prognosis in lung cancer57 but 
again not in breast. Therefore, our study revealed a novel miRNA-gene-survival association in breast cancer, that 
is supported by previous findings in lung cancer. Similar findings are the oncogene BIRC5, found relevant in 
LUAD here but only previously described in breast58, bladder59, chondrosarcoma60 and sarcoma61. However, its 
regulating miRNA (miR-145-5p) has been associated to prognosis in gastric62 and kidney63 tumours. Moreover 
CDC20, described as prognostic in colon64 and breast65, has been identified as relevant in KICH and LUAD in our 
study. Finally NCAPG and KIF20A genes of prognostic value in gliomas66,67 were found relevant here in LUAD. 
We also identified a few novel associations in lung tumours (LUAD), for instance CENPK has not previously 
been associated with this cancer type, even though the gene had already been associated to ovarian cancer68. 
When addressing the “exclusive lung interactions” the genes CDT1, CENPN, DAPK2, HJURP, KIF20A, NACPD2, 
NCAPG, NCAPH, SMC1B, and SPC24 have so far not been associated to survival in lung cancer, although most 
of its associated miRNAs have been. For instance miR-miR-1976 and miR-let-7b-5p miRNAs had already been 
associated to prognosis in lung cancer49,69, and in other tumours like breast70, prostate71, and gastric72. In conclu-
sion, our analysis has revealed novel miRNA-gene correlations that associate with patient prognosis, supported 
by previous findings on different tumour types.
To summarize, in addition to producing comparable results at the individual level, our integrative analysis 
provided a confident statistical approach to identify novel miRNA-target relationships in different tumour types 
within cancer-relevant pathways. The identification of lung exclusive mRNA/miRNA interactions that are sig-
nificantly associated with survival opens potentially avenues for clinical research into cancers. This exploratory 
analysis, followed by future experimental validation, could be significant to further decipher the role of miRNAs 
in tumorigenesis, confirming the validity of our approach to design of miRNA-targeted cancer drugs focusing on 
the gene/pathway. By confidently identifying specifically altered miRNA-mRNA pairs and interactions, off-target 
effects could be minimized, reducing side-effects and enhancing already existing treatments.
Methods
TCGA Transcriptome samples. A considerable number of tumour types, and the maximum number of 
control and tumour samples, are necessary to identify miRNA-mRNA associations related to common processes 
of tumorigenesis. As such, raw data sample files (fastq or bam files) from the TCGA database were used. These 
restricted samples were obtained by applying to the National Cancer Institute (NCI) and the National Human 
Genome Research Institute (NHGRI) from the National Institutes of Health (USA) for dbGAP-authorized access. 
Currently, TCGA includes data on 33 different tumour types obtained from different platforms. Since we are 
interested in the differential expression of genes and miRNAs implicated in tumour phenotypes, and their inter-
actions, we selected those tumours for which both kinds of transcriptome samples existed. After applying this 
initial filter, 19 tumour types with over 22,000 paired-end RNASeq and single-end miRNASeq samples were 
selected. Subsequently, to carry out a comprehensive statistical study by comparing controls with cancer samples, 
tumours with less than 10 healthy samples and those whose total number of healthy samples did not reach 5% of 
the total, were discarded. After applying these filters, 15 tumours were selected: Kidney Chromophobe (KICH), 
Head and Neck squamous cell carcinoma (HNSC), Oesophageal carcinoma (ESCA), Kidney renal papillary cell 
carcinoma (KIRP), Liver hepatocellular carcinoma (LIHC), Kidney renal clear cell carcinoma (KIRC), Lung 
Adenocarcinoma (LUAD), Thyroid carcinoma (THAD), Prostate adenocarcinoma (PRAD), Bladder Urothelial 
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Carcinoma (BLCA), Breast invasive carcinoma (BRCA), Lung squamous cell carcinoma (LUSC), Stomach adeno-
carcinoma (STAD), Cholangiocarcinoma (CHOL) and Uterine Corpus Endometrial carcinoma (UCEC). A total 
of 18,605 (6,867 RNASeq and 11,738 small-RNASeq) samples were recorded from these tumours and prepared 
for downloading from December 21st 2015 at the Cancer Genomics Hub (https://cghub.ucsc.edu/). Detailed 
information about the number of samples for each tumour is shown in Supplementary Table 1.
Selected pathways. In this study, we selected seven pathways that are highlighted as hallmarks of cancer4: 
the DDR and cell cycle pathways were chosen as characteristic of cancer checkpoints and development; telomere 
elongation and DNA replication are characteristic of tumour progression; and finally, apoptosis, necrosis and 
senescence were chosen given their role in inhibiting cancer. A total of 1,264 genes (861 unique) belonging to 
these pathways were identified, mainly from the Reactome73 and KEGG databases74. In the case of the DDR path-
way, the genes included were obtained from other published studies75 and retrieved from the DDRprot database76. 
All gene names and pathways, in which they participate, are shown in Supplementary Table 5.
Hyper-geometric pathway enrichment. In this work, seven cancer-related pathways were defined and 
the genes implicated were chosen from three different data sources. Since the classification of our pathways dif-
fers from those offered by enrichment analysis methods designed for NGS transcriptome sample analysis, we 
developed a statistical procedure based on an established approach for pathway analysis of cancer genomes77, 
enabling custom pathways to be integrated. Given our hypergeometric distribution, we used a Fisher’s exact test 
in a 2 × 2 contingency table to generate an odds ratio (OD) that quantifies the strength of enrichment, as well as 
a p-value corrected for multiple testing that estimates the proportion of enriched gene sets that would occur by 
chance given the number of gene sets tested based on the Benjamini-Hochberg method. While an OD > 1 for a 
given pathway means that the number of deregulated genes (either up-regulated or down-regulated) are positively 
enriched relative to all the genes expressed in the experiment (deregulated genes appear more than expected), an 
OD < 1 means that the given pathway is depleted in altered genes and consequently, it behaves like a healthy sam-
ple. As a control, differentially expressed genes equal in size to the number of genes within our described pathway 
were randomly selected to compare the Ors and adjusted p-values as shown in Supplementary Table 2. Ods for 
each of the tumour types are shown for any individual pathway in Fig. 2.
Transcriptome analysis of miRNAs and mRNAs. A total of 11,738 miRNA and 6,787 mRNA experi-
ments were downloaded from the controlled-access Cancer Genomics Hub. These samples were analysed follow-
ing the protocol proposed previously38 and using a pipeline for NGS studies called miARma-Seq78. Briefly, this 
tool brings together well-established software in a single bundle, allowing a complete analysis of the raw data. 
Quality analysis, adapter removal, read alignment, read count summarizing, differential expression analysis and 
gene pathway enrichment were performed, among others. For miRNA analysis, we employed miARma-Seq from 
the miRBase version 20 annotation database79, obtaining aligned reads for each mature miRNA. Similarly, the 
latest GRCh37 EnsEMBL version80 was used to acquire the total number of paired aligned reads for each human 
gene.
Statistical analysis of the transcriptome samples. To measure the miRNAs or genes differentially 
expressed in an independent cancer type, we compared the number of aligned reads associated with each miRNA/
gene in the control and tumour samples for each individual tumour. To achieve this, edgeR81 was used from the 
differential expression module included in miARma-Seq78. As recommended38, weakly expressed elements (miR-
NAs or genes) were filtered out if the CPM (counts per million reads) was < 1. Reads were normalized using the 
TMM method (trimmed mean of M-values) and the exact tests to calculate differences between two groups of 
negative-binomial counts was performed to gather the log2 fold change, and the Benjamini and Hochberg false 
discovery rate (FDR) for each miRNA/gene. The miRNAs or genes with a FDR < 0.05 were considered signifi-
cantly and reliably differentially expressed (DE). From these, those with an absolute log2 fold change (log2FC) 
value > 1 were selected for subsequent analyses (Supplementary Tables 6 and 7).
The miRNA-mRNA target prediction. Differentially expressed genes belonging to our seven defined 
pathways and miRNAs (FDR < 0.05) for each tumour analysed with an absolute log2FC ≥ 1 were chosen for target 
prediction. As miRNAs disrupt and reduce the expression of their target mRNAs, we expect miRNAs and mRNAs 
to exhibit an inverse expression profile. Thus, down-regulated mRNAs for a given tumour were used in the target 
prediction step for up-regulated miRNAs from the same tumour samples, and vice-versa. For miRNA-mRNA 
target predictions, we used miRGate29, a database of novel predicted miRNA–mRNA pairs computed from a 
common source of sequences. This repository includes a feature called “genomic agreement” that represents the 
number of unique predictions obtained from five different methods that occur in the same genomic position. 
Therefore, they are predicted from different prediction algorithms. To obtain reliable miRNA-mRNA pairs, only 
targets with an agreement value ≥ 2 were chosen.
Integrative analysis of all tumour types. Once all samples for each of the 15 tumour types were ana-
lysed, these results were studied in a global framework. As most of the oncogenes and tumour suppressor genes, 
and their oncomiR and anti-oncomiR regulators, appear to be misexpressed in tumours82, statistically deregulated 
genes and miRNAs (FDR ≤ 0.05 and log2FC ≥ 1) were extracted for each tumour type. Moreover, to decrease the 
number of false positives obtained from prediction algorithms, the miRNA target calculation step was improved 
by using inverse correlated profiles as recommended elsewhere20. Furthermore, genes and miRNAs were selected 
when both appeared to be differentially expressed in at least eight common tumour types, and only targets with a 
genomic agreement ≥ 2 were considered (Supplementary Table 8).
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In addition, in order to obtain highly specific miRNA-target associations conserved in the maximum number 
of tumour types as a representation of a shared deregulated mechanisms in cancer, we applied the following statis-
tical approach: for each partner in a miRNA-mRNA interaction, we computed all the possible  deregulated genes 
and miRNAs, respectively, to obtain the pair that is statistically enriched in the maximum number of tumours 
with fewer co-interactors. So for each miRNA, we obtained the gene(s) that could be potentially regulated in the 
maximum number of tumours and conversely, for each gene we obtained regulator miRNA(s) in the maximum 
number of tumours. This is implemented by computing a 2 × 2 contingency right-tailed Fisher exact test, measur-
ing all existing miRNA-target associations obtained through the differentially expressed genes and miRNAs in the 
majority of tumours included with a genomic agreement ≥ 2. P-values from fisher exact test were corrected from 
multiple testing using the Benjamini-Hochberg method83. For details of these pairs see Supplementary Table 9.
Identification of pairs belonging to the same tumour type. Differentially expressed genes and miR-
NAs for each individual tumour type were collected (Fig. 1), and like all the aforementioned analysis, we only 
considered those genes and miRNAs having a FDR < = 0.05 and a significant variation in expression (absolute 
log2FC > = 1). Once we had the set of statistically deregulated genes and miRNAs in each tumour type, we com-
puted all the possible miRNA-mRNA interactions using miRGate29 and selecting only those associations pre-
dicted by more than one algorithm in the same genomic position in the 3′ UTR (genomic agreement > = 2). 
Finally, once we have inferred this set of confident interactions, we first compare them among the 15 tumour 
types, to obtain a list of exclusive miRNA-mRNA interactions in each tumour type.
Analyses of methylation and copy number alterations in the pairs identified. The associa-
tion between gene and miRNA expression was analysed by multifactorial linear regression for every selected 
gene-miRNA pair, with the gene log-transformed RPKM values as the response and the miRNA log-transformed 
RPKM as the predictor (Supplementary Tables 11 and 12). To correct for putative confounding factors affect-
ing gene expression, copy number alterations (CNAs) and whole gene methylation (MET) were included in the 
models. For CNAs, Gistic2-preanalyzed data84 was downloaded directly from cBioportal85,86 and the information 
was coded as a categorical ordered factor with five different levels: homozygous deletion (− 2), hemizygous dele-
tion (− 1), no change (0), gain (1) and high level amplification (2). DNA methylation data was obtained from 
Wanderer, a web-based tool that offers convenient and fast access to gene-centred TCGA methylation data87. 
Methylation of cholangiomas (CHOL) was not available from Wanderer at the time. Thus, CHOL methylation 
data was directly downloaded from the cBioportal. For simplicity, all DNA methylation probes mapping within 
a particular gene locus were included in its regression models as independent factors. Methylation data was 
transformed from ß-values to M-values to reduce heterocedasticity before being included in the analyses88. All 
methylation probes used in the analysis are shown in Supplementary Table 10. For each mRNA-miRNA pair, we 
performed individual regression analyses for every individual cancer type in the study, plus an additional joint 
analysis that included all cancer types. To account for differences in gene expression and miRNA expression 
among cancer types, cancer type, and the statistical interaction between cancer type and miRNA expression were 
included as factors in the joint analyses. In all analyses, the gene-miRNA correlation was calculated as the squared 
root of the fraction of variance in gene expression explained by miRNA expression obtained by ANOVA with 
Type-III sum of squares, after accounting for the other factors, i.e.: cancer type and its interaction with miRNA 
expression (where applicable), CNAs and MET. The direction of the correlation, either positive or negative, as well 
as the t-statistic and the resulting P-value were calculated from the coefficients of the linear models. P-values were 
adjusted by the FDR method, taking into consideration that every mRNA-miRNA association was analysed in 16 
different datasets83. Regression could not be calculated in some cases where either the gene or the miRNA were 
not detected in the RNASeq data of a particular tumour type. In those cases, the correlation between gene and 
miRNA in that tumour type was considered to be non-existent. Details are available in Supplementary Tables 8 
and 1, Supplementary Figures 1 and 2.Only pairs exhibiting negative correlation between gene and miRNA 
expression, and with a P value < 0.05 after multi-hypothesis correction in the joint analysis, were selected for 
subsequent analyses (Supplementary Tables 11 and 12).
Survival analysis. For each gene-miRNA pair, the effect of gene and miRNA expression on patient sur-
vival was analysed by Cox’s proportional hazards modelling separately in every cancer type. All the models 
included tumour stage as a co-factor, coded into two categories: good prognosis (stages I or II) and bad prognosis 
(stages III, IV and X). In prostate cancer, the classification was performed based on tumour grade instead of 
tumour stage, where good prognosis involved tumours with Gleason score of 6 or 7, and bad prognosis tumours 
with Gleason score ≥ 8. In these analyses, gene or miRNA expression values were introduced as quantitative 
log-transformed variables. Multivariate Cox proportional hazards analysis provides an estimate of the effect of 
the gene/miRNA expression on survival, independently of the effect of tumour stage (or tumour grade, in the case 
of prostate cancer). P-values were adjusted by the FDR method83 and survival analyses are shown in Fig. 6 and 
Supplementary Figure 4. For details see Supplementary Tables 13 and 14.
The code to analyse the data can be found at https://github.com/amrojasmendoza/mRNA-miRNAs- 
cancer-pathways.
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